These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12385696)

  • 1. Comparison of telithromycin, a new ketolide, with erythromycin and clarithromycin for the treatment of Haemophilus influenzae pneumonia in suckling, middle aged and senescent mice.
    Thadepalli H; Chuah SK; Iskandar L; Gollapudi S
    Int J Antimicrob Agents; 2002 Sep; 20(3):180-5. PubMed ID: 12385696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
    Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
    J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae.
    Kosowska K; Credito K; Pankuch GA; Hoellman D; Lin G; Clark C; Dewasse B; McGhee P; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4113-9. PubMed ID: 15504829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis/pharyngitis: a multicenter, randomized, double-blind, parallel-group study.
    Quinn J; Ruoff GE; Ziter PS
    Clin Ther; 2003 Feb; 25(2):422-43. PubMed ID: 12749505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo efficacy of the new ketolide telithromycin (HMR 3647) in murine infection models.
    Bonnefoy A; Guitton M; Delachaume C; Le Priol P; Girard AM
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1688-92. PubMed ID: 11353612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults.
    Mathers Dunbar L; Hassman J; Tellier G
    Clin Ther; 2004 Jan; 26(1):48-62. PubMed ID: 14996517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae.
    Okamoto H; Miyazaki S; Tateda K; Ishii Y; Yamaguchi K
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3250-2. PubMed ID: 11600393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketolide treatment of Haemophilus influenzae experimental pneumonia.
    Piper KE; Rouse MS; Steckelberg JM; Wilson WR; Patel R
    Antimicrob Agents Chemother; 1999 Mar; 43(3):708-10. PubMed ID: 10049297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis.
    Hagberg L; Carbon C; van Rensburg DJ; Fogarty C; Dunbar L; Pullman J
    Respir Med; 2003 Jun; 97(6):625-33. PubMed ID: 12814146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia.
    Hagberg L; Torres A; van Rensburg D; Leroy B; Rangaraju M; Ruuth E
    Infection; 2002 Dec; 30(6):378-86. PubMed ID: 12478329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis.
    Norrby SR; Quinn J; Rangaraju M; Leroy B
    Clin Microbiol Infect; 2004 Jul; 10(7):615-23. PubMed ID: 15214873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides.
    Drago L; De Vecchi E; Nicola L; Colombo A; Gismondo MR
    J Antimicrob Chemother; 2004 Aug; 54(2):542-5. PubMed ID: 15215227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days.
    Tellier G; Chang JR; Asche CV; Lavin B; Stewart J; Sullivan SD
    Curr Med Res Opin; 2004 May; 20(5):739-47. PubMed ID: 15140341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin.
    Niederman MS; Chang JR; Stewart J; Nusrat R; Nieman RB
    Curr Med Res Opin; 2004 May; 20(5):749-56. PubMed ID: 15140342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of telithromycin compared with macrolides and fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
    Küçükbasmaci O; Gönüllü N; Aktaş Z; Gürol D; Berkiten R
    Int J Antimicrob Agents; 2003 Nov; 22(5):497-501. PubMed ID: 14602368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telithromycin: a brief review of a new ketolide antibiotic.
    Scheinfeld N
    J Drugs Dermatol; 2004; 3(4):409-13. PubMed ID: 15303785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F; Carnegy F; Willcock J; Amyes S
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials.
    Niederman MS; Chang JR; Stewart J; Asche CV; Lavin B; Nusrat R; Sullivan SD
    Curr Med Res Opin; 2004 Jul; 20(7):969-80. PubMed ID: 15265241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic modelling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages.
    Ikawa K; Kikuchi E; Kikuchi J; Nishimura M; Derendorf H; Morikawa N
    J Clin Pharm Ther; 2014 Aug; 39(4):411-7. PubMed ID: 24661290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora.
    Edlund C; Alván G; Barkholt L; Vacheron F; Nord CE
    J Antimicrob Chemother; 2000 Nov; 46(5):741-9. PubMed ID: 11062193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.